Copenhagen Acute Renal Complications After Transplantations Study Group
NCT ID: NCT02744872
Last Updated: 2016-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
42 participants
INTERVENTIONAL
2013-09-30
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to examine if calcium channel blockade administered before lung transplantation prevent cyclosporine induced nephropathy.
The design is an intention to treat randomized double blinded single center study. Patients are randomized to two groups, one that received felodipine and one that receives placebo.
Study population is all patients listed for lung transplantation in Denmark in the study period.
Intervention is tablet felodipine titrated to 10 mg, one daily dose in 12 weeks
Primary endpoint is change in renal function as measured by glomerular filtration rate using chromium-51 labeled ethylenediamine tetraacetic acid (51-Cr-EDTA) in the felodipine treated group compared with the placebo group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Renal Failure Following Lung Transplantation in Cystic Fibrosis Patients
NCT05001841
The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation
NCT03018041
Volatile Anesthetic Protection Of Renal Transplants 2
NCT02727296
Acute Pharmacokinetic-pharmacodynamic Change of Rocuronium After Reperfusion of Renal Graft
NCT02827435
Nutrient Levels Alter Transplant Outcome
NCT00560014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Calcium channel blockers exert renal effects consisting mainly of renal vasodilation and facilitation of renal excretion of sodium through a direct action on renal tubules. Calcium channel blockers improve renal function in cyclosporine treated transplant recipients through their effects in avoiding cyclosporine-induced renal vasoconstriction and facilitating renal sodium output.
Studies in both animal models and humans have demonstrated that calcium channel blockers maintain or reduce renal vascular resistance and preserve or enhance renal blood flow and glomerular filtration rate (GFR).
The aim of this study is to examine if calcium channel blockade administered before lung transplantation prevent cyclosporine induced nephropathy.
The design is an intention to treat randomized double blinded single center study. Patients are randomized to two groups, one that received felodipine and one that receives placebo.
Study population is all patients listed for lung transplantation in Denmark in the study period.
Sample size calculation estimated that 32 patients are needed, 16 patients in each group, with an estimated dropout incidence of 5 patients in each group. This will be able to detect an estimated 50% reduction in the decrease in measured GFR from 40 ml/min in the placebo group to 20 ml/min in treatment group, 80% power and a two-sided t-test, 5 % significance level.
Intervention is tablet Felodipine titrated to 10 mg, one daily dose in 12 weeks
Renal function is determined by 51-Cr-EDTA clearance measurement at times 0 before transplantation and after 1, 3 and 12 weeks.
Primary endpoint is change in renal function as measured by 51-Cr-EDTA clearance in the felodipine treated group compared with the placebo group.
Safety is monitored and adverse events are usually mild headache, tachycardia, leg edema, angina pectoris and hypotension.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Felodipine
Tablet Felodipin 10 mg x 1 daily
Felodipine
Felodipine 10 mg once daily or identical placebo
Placebo
Identical placebo once daily
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Felodipine
Felodipine 10 mg once daily or identical placebo
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients allergic to calcium antagonists
* Patients receiving treatment with Calcium antagonist 14 days prior to transplant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bo Feldt-Rasmussen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Feldt-Rasmussen
Role: PRINCIPAL_INVESTIGATOR
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet
Copenhagen Ø, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-004771-22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.